Difference between revisions of "Olanzapine (Zyprexa)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - ": new" to ": New") |
||
| Line 3: | Line 3: | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
| − | *2017-12-25: | + | *2017-12-25: New additional indication and a new dosage indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of antineoplastic drugs (cisplatin, etc.). |
==Also known as== | ==Also known as== | ||
*'''Brand name:''' Zyprexa | *'''Brand name:''' Zyprexa | ||
Latest revision as of 01:54, 11 June 2023
Mechanism of action
Atypical antipsychotic with antiemetic properties, likely through its effect on dopamine receptors. No known antineoplastic properties.
History of changes in PMDA indication
- 2017-12-25: New additional indication and a new dosage indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of antineoplastic drugs (cisplatin, etc.).
Also known as
- Brand name: Zyprexa